glp 1 liver glp-1 toxicity The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease GLP-1 Therapies May Benefit MPN

As part of Eli Lillys campaign against compounded GLP-1s, the company conducted testing of products marketed to contain tirzepatide and B12

This approach is inspired by the expert consensus statement by Sievenpiper and colleagues (2026) on nutritional management for individuals treated with GLP-1 receptor agonists

Azimzadeh, J

Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009

These steps should protect dry material

In this cohort study, most patients with overweight or obesity discontinued GLP-1 RA therapy within 1 year, but those without type 2 diabetes had higher discontinuation rates and lower reinitiation rates, the researchers concluded